10-Q: Theriva Biologics Q3 2025: Cash Extended, VCN-01 Advances

Theriva Biologics reports Q3 2025 results, extending cash runway into Q1 2027 and advancing its lead oncology candidate VCN-01 with positive clinical data.

Summary

• Net loss for the three months ended September 30, 2025, was $4.4 million, a decrease from $7.7 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $21.7 million, compared to $21.2 million for the nine months ended September 30, 2024.
• Cash and cash equivalents totaled $7.5 million as of September 30, 2025, but increased to $15.5 million in early November 2025 due to subsequent capital raises.
• A workforce reduction of approximately seven employees (32% of the global workforce) was implemented on September 30, 2025, expected to save $1.8 million annually in compensation and benefits.
• The company's cash runway is now expected to extend into the first quarter of 2027.
• Positive topline outcomes were announced from the VIRAGE Phase 2b clinical trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma (mPDAC), meeting primary survival and safety endpoints.
• Expanded mPDAC data from the VIRAGE Phase 2b trial, presented at ESMO 2025, showed improved overall survival (OS), progression-free survival (PFS), and duration of response (DoR) for VCN-01 combined with standard-of-care chemotherapy (GA) compared to GA alone.
• VCN-01 received Rare Pediatric Drug Designation (RPDD) from the FDA and Orphan Medicinal Product Designation from the EMA for the treatment of retinoblastoma.
• Preclinical data for VCN-12, a next-generation oncolytic adenovirus, demonstrated increased cell killing and hyaluronidase activity compared to VCN-01 in vitro, and significantly reduced tumor growth in animal studies.
• A $6 million milestone payment to Grifols for the VIRAGE Phase 2b success was deferred, with $500,000 paid in August 2025, $500,000 due by December 2025, and the remaining $5 million deferred until a licensing or business development transaction is secured.
• The company raised approximately $6.1 million in net proceeds from ATM sales and $4.4 million in gross proceeds from a warrant inducement agreement in October 2025.

Sentiment

Score: 6

Explanation: While the company faces significant going concern risks and has an accumulated deficit, the positive clinical trial results for VCN-01 in mPDAC, the extension of the cash runway, and successful capital raises post-Q3 provide a cautiously optimistic outlook for its lead oncology program. The strategic focus on VCN-01 and efforts to secure funding are positive, but the reliance on external funding for other programs and the ongoing going concern doubt temper the sentiment.

Positives

• Cash runway extended into the first quarter of 2027 due to restructuring and successful capital raises.
• Positive topline outcomes from the VIRAGE Phase 2b clinical trial for VCN-01 in mPDAC, meeting primary survival and safety endpoints.
• Expanded mPDAC data from the VIRAGE Phase 2b trial showed VCN-01 + GA improved OS (10.6 vs 8.6 months), PFS (5.6 vs 4.6 months), and DoR (11.2 vs 5.4 months) compared to GA standard of care.
• VCN-01 administration was well tolerated in the VIRAGE trial, with all VCN-01-related serious adverse events resolved and reduced frequency/grade of adverse events after the second dose.
• VCN-01 received Rare Pediatric Drug Designation (RPDD) for retinoblastoma from the FDA, potentially making the company eligible for a Priority Review Voucher if approved by September 30, 2026.
• VCN-01 received Orphan Medicinal Product Designation for retinoblastoma from the European Commission based on EMA recommendation.
• Preclinical data for VCN-12, a next-generation oncolytic adenovirus, showed increased cell killing compared to VCN-01 in vitro and significantly reduced tumor growth in animal studies.
• The THERICEL suspension cell platform is advancing for viral manufacturing, expected to increase efficiency and significantly reduce manufacturing costs for VCN-01 and other viral therapies.
• Secured a $1.4 million unsecured loan from the Spanish government for the THERICEL project.
• Successfully raised approximately $6.1 million in net proceeds from ATM sales and $4.4 million in gross proceeds from a warrant inducement agreement in October 2025.

Negatives

• Accumulated deficit of $356.7 million as of September 30, 2025, and recurring operating losses since inception (with minor exceptions).
• Substantial doubt about the company's ability to continue as a going concern beyond the next twelve months without additional capital or strategic actions.
• A workforce reduction of 32% (7 employees) was implemented, indicating financial strain and the need for significant cost-cutting measures.
• A $5 million portion of the $6 million milestone payment to Grifols for VIRAGE success is deferred until a licensing or business development transaction is secured, highlighting reliance on future deals.
• The company does not anticipate funding the last cohort of the SYN-004 Phase 1b/2a trial without grant funding or a licensee/partner, indicating a halt in internal development for this program.
• Exploring out-licensing or partnering for SYN-004 and SYN-020 assets, signaling a strategic shift away from internal development for these programs.
• The ability to raise capital through the ATM Sales Agreement is limited by SEC rules and the market value of voting securities held by non-affiliates.
• The U.S. federal government shutdown may delay regulatory review processes, affect capital markets transactions, and hinder FDA interactions.
• General and administrative expenses increased significantly to $14.5 million for the nine months ended September 30, 2025, primarily due to a $9.2 million increase in the fair value of contingent consideration adjustment.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and an accumulated deficit of $356.7 million.
• Need to raise additional capital to fund operations and meet current timelines, with no assurance that funding will be available on acceptable terms or at all.
• Potential for significant dilution for existing stockholders if funds are raised by issuing additional equity securities.
• Debt financing, if available, may involve restrictive covenants that could impact business operations and have a dilutive effect on stockholders.
• Failure to secure additional funds could force delays, reductions, or elimination of development programs or commercialization efforts, or even cessation of operations.
• Ability to raise capital through the ATM Sales Agreement is limited by SEC rules and NYSE American rules, particularly if the market value of voting securities held by non-affiliates is less than $75 million.
• May be required to seek collaborators for product candidates at an earlier stage than desirable and on less favorable terms.
• Changes to trade policy, including tariffs and customs regulations, or failure to comply with such regulations, may adversely affect reputation, business, financial condition, and results of operations.
• A prolonged or recurring U.S. federal government shutdown may delay regulatory review processes, impact access to capital markets, hinder strategic transactions, and increase legal and compliance risks.
• Inadequate funding for the FDA, SEC, and other government agencies could hinder their ability to perform normal business functions, delaying product development and approvals.
• Clinical trials dependent on federal grant funding are at risk from government shutdowns, potentially disrupting the timing and availability of these funds.
• Uncertainty regarding how a new administration will modify or revise the requirements and policies of the FDA and other regulatory agencies.
• If the $5 million deferred milestone payment to Grifols is required, it will significantly deplete cash and cash equivalents, adversely affecting liquidity.
• Estimates of workforce reduction charges and timing are subject to assumptions, and actual amounts may differ materially from estimates.
• Inherent uncertainties in making accounting estimates related to goodwill, in-process research and development (IPR&D), research and development costs, and contingent consideration.
• Risks related to the progress and scope of research activities, ability to recruit patients for clinical studies in a timely manner, preclinical and clinical development activities, manufacturing costs, patent prosecution and enforcement, and the costs and timing of regulatory approvals.

Future Outlook

Management believes the company's current cash position of $15.5 million (as of early November 2025) will be sufficient to fund operations into the first quarter of 2027. The strategic focus is on regulatory interactions for potential pivotal clinical trials of VCN-01 in mPDAC and retinoblastoma, exploratory VCN-01 manufacturing scale-up activities, and limited preclinical research. Additional funding will be required for future clinical trials of VCN-01, SYN-004, or SYN-020, with SYN-004 development contingent on securing grant funding or a partner. The company is actively pursuing additional equity or debt financing and strategic collaborations.

Management Comments

• "The goal of this reduction is to direct our resources towards business development and licensing activities and clinical trial planning and preparation for potential pivotal trials of VCN-01 in patients with PDAC and retinoblastoma, which it believes will represent its best opportunity for success."
• "Based upon our current business plans, management believes that the Companys current cash on hand of $15.5 million in early November 2025 will be sufficient to fully execute its plans through the fourth quarter of 2026 and into the first quarter of 2027."
• "Management believes its plan, which is focused on the advancement of VCN-01, will allow us to meet our financial obligations, further advance key products, and maintain our planned operations."
• "Based upon our current available funding and our focus on our clinical development of VCN-01 we do not anticipate that we will fund the last cohort of the Phase 1b/2a clinical trial of SYN-004 and enrollment in this cohort will not commence unless we obtain grant funding, or find a licensee or partner for the SYN-004 development program."

Industry Context

Theriva Biologics is strategically transitioning to an oncology-focused clinical-stage biopharmaceutical company, emphasizing oncolytic virotherapy. This aligns with a broader industry trend towards developing innovative cancer therapies, including gene and cell therapies, particularly for difficult-to-treat cancers like mPDAC and retinoblastoma, which represent high unmet medical needs. The development of next-generation oncolytic adenoviruses (VCN-X) and proprietary manufacturing platforms (THERICEL) demonstrates a commitment to innovation within the gene/cell therapy space. The decision to explore out-licensing or partnering for its gastrointestinal assets (SYN-004, SYN-020) reflects a strategic prioritization of the oncology pipeline, a common practice for smaller biotechs to focus resources on their most promising candidates.

Comparison to Industry Standards

• In the VIRAGE Phase 2b trial, patients receiving VCN-01 + gemcitabine/nab-paclitaxel (GA) showed greater improvement in overall survival (14.8 vs 11.6 months; HR 0.44; P=0.046) and progression-free survival (11.2 vs 7.4 months; HR 0.48; P=0.017) compared to patients who started GA cycle 4 alone (Arm I).
• The EMA's Committee for Orphan Medicinal Products (COMP) noted that the potential benefit of VCN-01 in a Phase 3 trial will be compared with the therapeutic effects of other approved standard-of-care chemotherapies (FOLFIRINOX, NALIRIFOX) when considering maintenance of Orphan Medicinal Product status.
• Preclinical data for VCN-12 showed increased cell killing compared to VCN-01 in a variety of cancer cell models in vitro, indicating potential improvement over the company's lead candidate.
• Intratumoral VCN-12 significantly reduced tumor growth compared to VCN-01 in immunocompetent hamsters bearing HP-1 pancreatic tumors.
• Initial VCN-01 clinical data from studies suggest that administration of VCN-01 may increase tumor immunogenicity and improve access of huCART-meso cells to tumor cells, addressing challenges encountered by huCART-meso cells in previous clinical studies by Dr. Carl June's laboratory.
• In the Phase 1 trial of huCART-meso cells with VCN-01, 66.6% (4 out of 6) patients with measurable disease receiving huCART-meso after VCN-01 showed tumor shrinkage, indicating a promising trend in disease stabilization compared to either agent alone.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on the business, operating results, financial condition, or cash flows.

Related Party Transactions

• MaryAnn Shallcross, the wife of Steven Shallcross (Chief Executive Officer and Chief Financial Officer), was employed as Director of Clinical Operations. For the nine months ended September 30, 2025, the company incurred $117,000 in compensation expense related to Ms. Shallcross and granted her an option to purchase 25,000 shares of Common Stock valued at $27,000. Her employment was terminated as part of the company's workforce reduction on September 30, 2025.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity raises, but may benefit from positive clinical data for VCN-01 and the extended cash runway. The ongoing 'going concern' doubt and workforce reduction are negative factors.
• Employees are directly impacted by the workforce reduction of 32% (7 employees), including a key management role, indicating job insecurity and restructuring.
• Creditors may view the 'going concern' doubt as a risk, although the extended cash runway and capital raises provide some short-term stability. The deferral of a $5 million milestone payment to Grifols highlights financial constraints.
• Patients and the medical community could benefit from the advancement of VCN-01 in mPDAC and retinoblastoma, offering potential new therapeutic options for diseases with high unmet needs.
• Partners and collaborators are crucial for the company's future, especially for funding SYN-004 development and the deferred Grifols milestone payment, indicating a reliance on external strategic relationships.

Next Steps

• Focus on business development and licensing activities.
• Engage in upcoming meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for planned pivotal clinical trials of VCN-01 in mPDAC and retinoblastoma.
• Continue exploratory VCN-01 manufacturing scale-up activities.
• Continue limited preclinical research efforts for VCN-01 and VCN-12.
• Actively pursue additional equity or debt financing or strategic relationships to fund future clinical trials.
• Explore out-licensing or partnering for SYN-004 and SYN-020 assets.
• Plan further preclinical studies for VCN-12.
• Seek stockholder approval for the full exercise of the New Warrants and the issuance of all shares of common stock issuable upon their exercise.

Key Dates

Recommendation

While Theriva Biologics has demonstrated promising clinical results for its lead oncology candidate VCN-01 in metastatic pancreatic cancer and retinoblastoma, and has extended its cash runway into Q1 2027 through strategic financing and cost reductions, significant going concern risks persist. The company continues to incur substantial losses and relies heavily on future capital raises and partnerships to fund pivotal clinical trials. The strategic shift away from internal development of GI assets (SYN-004, SYN-020) to focus on VCN-01 is a clear prioritization, but the success of VCN-01 is still subject to large, expensive future trials and regulatory approvals. The recent capital raises are positive, but the company's ability to secure sufficient long-term funding remains uncertain, especially given SEC limitations on ATM sales. Investors should hold, monitoring progress on VCN-01's regulatory path and the company's ability to secure necessary financing and partnerships.

Keywords

Theriva Biologics, TOVX, 10-Q, Q3 2025, financial results, oncology, VCN-01, pancreatic cancer, retinoblastoma, oncolytic virus, VIRAGE trial, mPDAC, RPDD, Orphan Drug Designation, EMA, FDA, clinical trials, cash runway, capital raise, ATM offering, warrant exercise, workforce reduction, SYN-004, SYN-020, biopharmaceutical, clinical-stage, gene therapy, cell therapy